Search clinical trials for: OVAnex

Total 156 results

Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
Biogen

Completed

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Multiple Sclerosis | Pregnancy | Prenatal Exposure Delayed Effects

United States
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Biogen

Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis

United States, Canada, Czech Republic, Hungary, Poland, Russian Federation, Slovakia
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
Biogen

Terminated

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (BRAVO)

Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Washington University School of Medicine

Completed

Actinic Keratosis Study (AK)

Actinic Keratosis

United States
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Eunice Kennedy Shriver National Institute of Child...

Completed

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

Healthy | Cushing's Syndrome | Adrenal Gland Hyperfunction | Adrenal Gland Hypofunction

United States
Wake Forest University Health Sciences

Active, not recruiting

Hidradenitis Suppurativa Wound Care

Hidradenitis Suppurativa (HS)

United States
EMD Serono Research & Development Institute, Inc.

Completed

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (ONWARD)

Multiple Sclerosis

United States, Italy, Russian Federation, Spain
Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Russian Federation
Yale University
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

Hematologic Malignancies

United States
Biogen

Active, not recruiting

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CONNECT)

Relapsing-Remitting Multiple Sclerosis

Italy, Belgium, United States, Hungary, Sweden, United Kingdom, Israel, France, Czechia, Poland, Serbia, Denmark, Spain, Turkey, Bulgaria, Germany, Canada, Kuwait
Louisiana State University Health Sciences Center...
Biogen

Completed

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Multiple Sclerosis

United States
Biogen

Completed

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Multiple Sclerosis

United States
University of California, Los Angeles
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"

Acne Vulgaris

United States
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
Biogen

Recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis

Spain, Switzerland, Ireland, United States, Germany
Biogen

Completed

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)

Multiple Sclerosis

Denmark
Novartis Pharmaceuticals

Completed

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (EPOC)

Relapsing Remitting Multiple Sclerosis

Italy
Novartis Pharmaceuticals

Completed

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (EPOC)

Relapsing Forms of Multiple Sclerosis

United States, Canada, Puerto Rico
Nancy Hammond, MD
Kansas City Area Life Sciences Institute, Inc.

Completed

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Multiple Sclerosis | Low Bone Density

United States
Biogen

Completed

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta (RENeu)

Relapsing-Remitting Multiple Sclerosis

New Zealand, Australia
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (RADIANCE)

Relapsing Multiple Sclerosis

Spain, United States, United Kingdom, Croatia, Serbia, Belarus, Hungary, Bulgaria, Poland, Italy, Ukraine, Greece, Belgium, Georgia, Bosnia and Herzegovina, Moldova, Republic of, Romania, Russian Federation, Slovakia, South Africa and more
University of California, San Francisco
Oregon Health and Science University; National Multiple Sclerosis Society

Completed

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

Multiple Sclerosis

United States
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Incyte Corporation

Completed

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Psoriasis

United States
Mallinckrodt
PRA Health Sciences

Terminated

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

Acute Graft-versus-Host Disease

United States, Canada, Germany, United Kingdom, Australia, Austria, Belgium, Italy, France, Netherlands, Switzerland
Teva Neuroscience, Inc.

Completed

Therapy Optimization in Multiple Sclerosis (MS) (TOP MS)

Multiple Sclerosis

United States
Biogen

Completed

Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies (RECOVER)

Relapsing-Remitting Multiple Sclerosis

Finland
National Cancer Institute (NCI)

Recruiting

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Actinic Keratosis

United States
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, Spain, Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Glioblastoma | Malignant Glioma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Astrocytoma, Grade III | Brain Stem Neoplasms, Malignant | Oligodendroblastoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Bayer
Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.

Not yet recruiting

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)

Multiple Sclerosis (MS)

Sweden, Finland
Centro Cardiologico Monzino

Completed

pLatelEts And MigRaine iN patEnt foRamen Ovale (LEARNER)

Patent Foramen Ovale | Migraine With Aura | Platelet Aggregation, Spontaneous

Italy
University of Michigan Rogel Cancer Center
Amgen; Mallinckrodt

Completed

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Graft Versus Host Disease

United States
Zahra Vahdat Shariatpanahi

Completed

Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

Helicobacter Infection

Iran, Islamic Republic of
Sanofi

Completed

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (TERIVA)

Multiple Sclerosis

Germany, Ukraine, Canada, Austria, Russian Federation
University of Michigan

Completed

Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures

Stress

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
LEO Pharma
Quintiles, Inc.

Completed

LEO 90105 Ointment in Japanese Subjects With Psoriasis

Psoriasis

Japan
Sanofi

Completed

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, United Kingdom, Austria
Bayer
Novartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe Ltd

Completed

EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis

Finland
University of British Columbia

Unknown

Nickel Desensitization Using Topical Therapy

Allergic Contact Dermatitis

Canada
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Breast Cancer

Greece

Search clinical trials for: OVAnex

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations